The Efficacy and Safety of Apatinib Combined With Etoposide in Heavily Pretreated Advanced Non-small Cell Lung Cancer

Inclusion Criteria: * Obtain of informed consent. * Histologically or cytologically confirmed non-small cell lung cancer. * World Health Organization (WHO) performance status (PS) of 0 to 2. * Measurable lesions as defined by RECIST criteria. * Second-line or more treatments. * Wild type of epidermal-growth-factor receptor (EGFR). * Life expectancy ≥12 weeks. * Organ functions normal, as defined below, within two weeks of randomization: • Hb≥90g/L Absolute neutrophils count(ANC)≥1.5×109/L Platelets≥80×109/L Serum bilirubin≤2×ULN; Aspartate transaminase(AST) and alanine transaminase (ALT)≤2.5×ULN(≤5×ULN if liver metastases) Creatinine clearance≥45ml/min or Cr≤1.25×ULN. * Females of child-bearing potential must have negative serum pregnancy test. * Sexually active males and females (of childbearing potential) willing to practice contraception during the study. Exclusion Criteria: * Small cell lung cancer. * Newly diagnosed Central Nervous System (CNS) metastases that have not yet been definitively treated with surgery and/or radiation. * Uncontrolled hypertension. * Myocardial ischemia or infarction more than stage II, cardiac insufficiency. * Abnormal coagulation (INR\>1.5 or PT\>ULN+4, or APTT\>1.5 ULN), bleeding tendency or receiving coagulation therapy. * Difficulties in taking pills (inability to swallow tablets,GI tract resection, chronic bacillary diarrhea and intestinal obstruction). * Hemoptysis, more than 2.5ml daily. * Thrombosis in 12 months, including pulmonary thrombosis, stoke, or deep venous thrombosis. * Unhealed bone fracture or wound for long time. * Received big surgery, had bone fracture or ulcer in 4 weeks. * Urine protein≥++, or urine protein in 24 hours≥1.0g. * Pregnant or lactating woman.